Want to see AU:MSB full AI Analyst Report?

Mesoblast Limited (MSB) Price & Analysis

327 Followers

MSB Stock Chart & Stats

AU$2.35

-AU$0.08(-3.60%)

At close: Jul 27 4:00 PM EDT

AU$2.35

-AU$0.08(-3.60%)

Day’s Range― - ―

52-Week RangeAU$1.74 - AU$3.31

Previous CloseN/A

Volume2.85M

Average Volume (3M)3.27M

Market Cap

AU$2.29B

Enterprise ValueAU$3.52B

Total Cash (Recent Filing)AU$47.39M

Total Debt (Recent Filing)AU$127.33M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Mar 04, 2027

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding1,301,298,100

10 Day Avg. Volume5,182,204

30 Day Avg. Volume3,266,109

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)3.09

Price to Sales (P/S)14.29

P/FCF Ratio-39.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$3.59

Price Target Upside52.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.02

Revenue Forecast (FY)AU$209.64M

Bulls Say, Bears Say

Bulls Say

Ryoncil Commercial TractionRyoncil has moved Mesoblast from a primarily development-stage revenue model toward meaningful commercial execution. Strong early sales, broad payer coverage, and management’s revenue guidance provide a foundation for continued adoption and greater operating scale over the next several quarters.

High Gross-margin PotentialThe very high gross margin on Ryoncil indicates attractive underlying product economics once commercial volume is established. If revenue growth continues, this margin structure could help absorb fixed commercial and development costs and support future operating leverage.

Clinical Pipeline And Regulatory ProgressPositive clinical results and an advancing BLA create a credible pathway to expand Mesoblast’s product portfolio beyond Ryoncil. Additional indications could broaden future revenue sources, improve the company’s strategic position, and reduce dependence on one commercial asset if approvals are achieved.

Bears Say

Persistent Losses And Cash BurnMesoblast has not yet converted its revenue growth into sustainable profitability or positive cash generation. Continued operating and free-cash-flow deficits can consume balance-sheet resources, increase reliance on financing, and constrain investment flexibility until the business reaches sufficient scale.

Dependence On RyoncilThe concentration of revenue in one product leaves company performance highly dependent on Ryoncil’s adoption, reimbursement, and execution. A setback affecting that product could materially weaken near-term growth and cash generation because pipeline candidates are not yet established commercial contributors.

Escalating Development ExpenditureThe sharp increase in R&D spending raises the investment required to advance the pipeline and prepare regulatory submissions. Unless these programs generate approvals and future revenue, elevated development costs will prolong losses, increase cash needs, and make earnings improvement dependent on successful execution.

Mesoblast Limited News

Mesoblast receives FDA approval for potency assay to release Ryoncil product

Mesoblast (MESO) announced that it has received approval from the United States Food and Drug Administration, FDA, to...

29d ago

MESO

Mesoblast Sets Details for 2026 Annual General Meeting

The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast Limited has announced details for its...

11d ago

Mesoblast Files Updated Corporate Governance Statement and ASX Appendix 4G

Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. Mesoblast Limited has lodged its updated corporate governance statement...

11d ago

State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold

Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. State Street Corporation, through a group of asset management...

22d ago

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for...

29d ago

State Street Group Ceases to Be Substantial Holder in Mesoblast

Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. State Street Corporation and several of its asset management...

1M ago

Mesoblast price target raised to $39 from $35 at Piper Sandler

Piper Sandler raised the firm’s price target on Mesoblast (MESO) to $39 from $35 and keeps an Overweight...

2M ago

MESO

Mesoblast revenue surges on RYONCIL launch as late‑stage pipeline advances

Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast reported a sharp increase in full‑year revenue to...

2M ago

Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy

The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast issued a financial results and operational...

2M ago

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited has filed its annual report...

2M ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Rezolve AI Ltd (RZLV)...

2M ago

HYG

Mesoblast Increases Director Philip Krause’s Equity-Based Incentives

Mesoblast Limited ( ($AU:MSB) ) just unveiled an announcement. Mesoblast Limited has disclosed a change in Director Philip...

2M ago

Mesoblast Issues 875,000 Unquoted Employee Incentive Options

Mesoblast Limited ( ($AU:MSB) ) has shared an update. Mesoblast Limited has notified the market of the issue...

2M ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: iShares US Medical Devices...

2M ago

MSB FAQ

What was Mesoblast Limited’s price range in the past 12 months?

Mesoblast Limited lowest share price was AU$1.74 and its highest was AU$3.31 in the past 12 months.

What is Mesoblast Limited’s market cap?

Mesoblast Limited’s market cap is AU$2.29B.

When is Mesoblast Limited’s upcoming earnings report date?

Mesoblast Limited’s upcoming earnings report date is Mar 04, 2027 which is in 132 days.

How were Mesoblast Limited’s earnings last quarter?

Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.034.

Is Mesoblast Limited overvalued?

According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast Limited pay dividends?

Mesoblast Limited does not currently pay dividends.

What is Mesoblast Limited’s EPS estimate?

Mesoblast Limited’s EPS estimate is -0.02.

How many shares outstanding does Mesoblast Limited have?

Mesoblast Limited has 1,301,298,100 shares outstanding.

What happened to Mesoblast Limited’s price movement after its last earnings report?

Mesoblast Limited reported an EPS of -AU$0.044 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.

Which hedge fund is a major shareholder of Mesoblast Limited?

Currently, no hedge funds are holding shares in AU:MSB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mesoblast Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-10.06%

Trailing 12-Months

Asset Growth

-1.48%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Mesoblast Limited

Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.

Mesoblast Limited (MSB) Earnings & Revenues

Historic Earnings Reports

MSB Stock 12 Month Forecast

Average Price Target

AU$3.59

▲(52.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"AU$1","2":"AU$2","3":"AU$3","4":"AU$4","5":"AU$5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$4.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5866666666666673,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$3.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$2.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2,3,4,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.249230769230769,2.4284615384615384,2.6076923076923078,2.786923076923077,2.9661538461538464,3.1453846153846152,3.3246153846153845,3.503846153846154,3.683076923076923,3.8623076923076924,4.041538461538462,4.220769230769231,{"y":4.4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.1866666666666665,2.3033333333333332,2.42,2.5366666666666666,2.6533333333333333,2.7700000000000005,2.8866666666666667,3.003333333333334,3.12,3.2366666666666672,3.3533333333333335,3.4700000000000006,{"y":3.5866666666666673,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.126153846153846,2.1823076923076923,2.2384615384615385,2.2946153846153843,2.3507692307692305,2.4069230769230767,2.463076923076923,2.519230769230769,2.575384615384615,2.6315384615384616,2.6876923076923074,2.7438461538461536,{"y":2.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >